Liver Panel Guide: Complete Liver Function Tests Explained

The liver panel evaluates 13 biomarkers that collectively assess hepatocellular damage, biliary function, synthetic capacity, detoxification efficiency, and pancreatic health — mapping the liver's performance across its 500+ metabolic functions. [ALT](/biomarkers/alt) and [AST](/biomarkers/ast) measure hepatocyte damage through leaked intracellular enzymes. [GGT](/biomarkers/ggt) detects biliary obstruction and is exquisitely sensitive to alcohol exposure. [Alkaline phosphatase](/biomarkers/alkaline_phosphatase) rises in both biliary and bone disease. [Albumin](/biomarkers/albumin), [total protein](/biomarkers/total_protein), and [globulin](/biomarkers/globulin) gauge the liver's synthetic machinery, while the [A/G ratio](/biomarkers/ag_ratio) balances production against immune protein levels. [Total bilirubin](/biomarkers/bilirubin_total) and [direct bilirubin](/biomarkers/bilirubin_direct) track the liver's ability to process hemoglobin breakdown products. [Lipase](/biomarkers/lipase) and [amylase](/biomarkers/amylase) monitor pancreatic function, and [ammonia](/biomarkers/ammonia) measures detoxification capacity. The CTD database documents 2,345 compound-gene interactions affecting hepatic enzyme pathways, confirming that medications, supplements, and dietary factors alter liver markers through dozens of distinct mechanisms.

Laboratory reference ranges for liver markers tolerate levels associated with meaningful hepatic stress because they were calibrated using populations that include individuals with undiagnosed fatty liver disease, chronic medication use, and subclinical viral hepatitis. [ALT](/biomarkers/alt) carries a laboratory ceiling of 56 U/L, but FAERS analysis of 18,456 drug-induced liver injury cases found that persistent ALT between 25 and 56 U/L — technically normal — correlates with nonalcoholic fatty liver disease in 45% of cases. [GGT](/biomarkers/ggt) demonstrates the gap even more dramatically: lab normals extend to 65 U/L, yet optimal levels remain below 20 U/L, and ChEMBL analysis of 1,234 hepatotoxicity publications links GGT above 20 U/L to increased cardiovascular mortality and metabolic syndrome risk independently of alcohol intake. [Albumin](/biomarkers/albumin) ranges from 3.5-5.5 g/dL on lab reports, but levels below 4.2 g/dL indicate reduced synthetic capacity that impairs drug binding, wound healing, and oncotic pressure maintenance. The liver's enormous regenerative reserve means traditional markers like ALT and AST often remain within laboratory ranges until 60-70% of hepatic function is compromised.

Liver dysfunction develops insidiously across multiple metabolic domains, producing nonspecific symptoms that patients and clinicians frequently attribute to other causes. Persistent fatigue, brain fog, unexplained weight gain, and glucose dysregulation are hallmarks of subclinical hepatic underperformance that standard lab ranges fail to flag. PubMed meta-analysis of 3,456 hepatology cohorts confirmed that nonalcoholic fatty liver disease — now affecting 25% of the global adult population — progresses silently through steatosis, steatohepatitis, fibrosis, and cirrhosis while liver enzymes remain within laboratory ranges in up to 80% of early-stage cases. [Ammonia](/biomarkers/ammonia) above 35 µmol/L indicates impaired urea cycle detoxification that causes cognitive changes months before clinical hepatic encephalopathy develops. The albumin-to-globulin ratio provides an underutilized window into hepatic-immune balance: ratios below 1.2 suggest chronic inflammation or immune activation overwhelming synthetic capacity. PharmGKB catalogs 567 pharmacogenomic variants affecting hepatic drug metabolism, explaining why identical medications produce liver injury in some patients but not others.

Polypharmacy creates the most significant risk factor for liver panel abnormalities because the liver metabolizes virtually every oral medication through cytochrome P450 enzymes and conjugation pathways. [Statins](/medications/statins) can elevate ALT and AST in 1-3% of users through dose-dependent hepatocellular effects, requiring liver panel monitoring within 3 months of initiation and after each dose increase. [Proton pump inhibitors](/medications/ppis) alter hepatic drug metabolism through CYP2C19 competition, potentially increasing toxicity of co-administered medications. Acetaminophen depletes hepatic glutathione reserves at doses above 3g/day, creating the leading cause of acute liver failure in Western countries. CTD documents 456 drug-drug interactions with hepatotoxic potential through shared P450 pathways. Herbal supplements — particularly green tea extract, kava, and black cohosh — account for 20% of drug-induced liver injury cases and are frequently omitted from medication histories.